PRESS RELEASE published on 05/14/2024 at 22:05, 1 year 10 months ago Protagonist Therapeutics Announces Oral Presentation on Long-Term Follow-up of Rusfertide Phase 2 REVIVE Study Open Label Extension at the European Hematology Association 2024 Congress Protagonist Therapeutics to present rusfertide Phase 2 REVIVE study data at EHA Congress in Madrid. Study shows absence of QTc prolongation with rusfertide. Details on pipeline drugs and collaborations available on company's website Clinical Development Collaborations Protagonist Therapeutics Rusfertide EHA Congress
Published on 03/26/2026 at 21:00, 46 minutes ago Worksport Reports Record FY 2025 Results, Issues $35M–$42M 2026 Revenue Guidance; Targets Initial Cash Flow Positivity
Published on 03/26/2026 at 21:00, 46 minutes ago Rocky Shore Closes Acquisition of Additional Mining Claims
Published on 03/26/2026 at 16:20, 5 hours 26 minutes ago ACCESS Newswire Upgrades the ACCESS Platform to Include Social Monitoring to Track Brand Conversations Across Major Social Platforms
Published on 03/26/2026 at 13:00, 8 hours 46 minutes ago Prospect Ridge Strengthens Technical Team with Appointment of Phil Smerchanski as Senior Technical Advisor
Published on 03/26/2026 at 20:48, 58 minutes ago Dermapharm Holding SE repurchases 4,299,190 shares under its public share buyback offer
Published on 03/26/2026 at 19:20, 2 hours 26 minutes ago Critical Path Institute Launches 'One to Millions' to Reshape the Future of Individualized Medicine at Global Scale
Published on 03/26/2026 at 19:09, 2 hours 37 minutes ago 2CRSi SA: Résultats 1er Semestre 2025/26 : Chiffre d'Affaires 204,7 M€ (x9,8) EBITDA de 9,6 M€ (x4,6)
Published on 03/26/2026 at 19:09, 2 hours 37 minutes ago 2CRSi SA: First Half 2025/26 Results: Revenue of €204.7 million (x9.8) EBITDA of €9.6 million (x4.6)
Published on 03/26/2026 at 18:17, 3 hours 29 minutes ago Eiffage se renforce au capital de Getlink et porte sa participation à 29,40 % du capital
Published on 03/26/2026 at 18:17, 3 hours 29 minutes ago Eiffage strengthens its position in Getlink capital
Published on 03/26/2026 at 18:00, 3 hours 46 minutes ago Arrêté des comptes au 31 décembre 2025 et perspectives 2026
Published on 03/26/2026 at 18:00, 3 hours 46 minutes ago LABORATOIRES EUROMEDIS - Fin du contrat de liquidité